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Abstract 17 
In this work a novel multi-microfluidic crystallization platform called MMicroCryGen is 18 
presented, offering a facile methodology for generating individual crystals for fast and easy 19 
screening for polymorphism and crystal habit of solid compounds. The MMicroCryGen 20 
device is capable of performing 8×10 cooling crystallization experiments in parallel using 8 21 
disposable microcapillary film strips, each requiring less than 25 µL of solution. Compared to 22 
traditional microfluidic systems the MMicroCryGen platform does not require complex fluid 23 
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handling, it can be directly integrated with a 96 wells microplate and it can also work in 24 
“dipstick” mode. The produced crystals can be safely and directly observed inside the 25 
capillaries with optical and spectroscopic techniques. The platform was validated by 26 
performing a number of independent experimental runs for: (1) polymorph and hydrate 27 
screening for ortho-aminobenzoic acid, succinic acid and piroxicam; (2) co-crystal form 28 
screening for the p-Toluenesulfonamide/triphenylphosphine oxide system; (3) studying the 29 
effect of o-toluic acid on ortho-aminobenzoic cooling crystallization (effect of structurally 30 
related additives). In all three cases, all known solid forms were identified with a single 31 
experiment using ∼200 µL of solvent and just few micrograms of solid material. The 32 
MMicroCryGen is simple to use, inexpensive and it provides increased flexibility compared 33 
to traditional crystallization techniques, being an effective new microfluidic solution for solid 34 
form screening for pharmaceutical, fine chemicals, food and agrochemical industries.  35 
  36 
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Introduction 37 
Polymorphism is known as the ability of a compound to exist in more than one crystalline 38 
structure and is very common in the crystallization of active pharmaceutical ingredients 39 
(APIs) (1). Polymorph screening is therefore essential during the development of new drugs 40 
since the formation of the wrong polymorph can affect solubility, rate of dissolution and 41 
toxicity of the API (1-3). The discovery of possible polymorphic forms for newly synthesized 42 
compounds is usually done by running independent crystallization experiments in small, 43 
bench scale (1-100 mL) crystallizers or via high-throughput devices based on arrays of wells, 44 
tubes or vials. This task requires a large number of steps and it is often difficult and 45 
expensive to automate because of the complex fluid handling involved (4, 5). Robotic liquid 46 
handling systems provided the mean to automate and increase throughput for screening of 47 
novel compounds in a drug discovery environment (6); however, the high cost of such 48 
systems means the technology is only accessible to few.  49 
In recent years microfluidic devices have been used to study several crystallization steps, 50 
including nucleation and growth (7-11), polymorphism (12-14) and co-crystal formation (15). 51 
Microfluidic technologies offer the possibility of running several experiments in parallel 52 
using small quantities of API, which is particularly important during the early stages of 53 
clinical trials when only small quantity of API is available. Nevertheless, current microfluidic 54 
devices still require interface to complex fluid handling (16). Furthermore, the extraction of 55 
crystals from the microfluidic channels for off-line analysis can also be problematic. 56 
Droplet-based devices are the most commonly used microfluidic tools for measuring 57 
nucleation rate, metastable zone width as well as solubility, and for the screening of 58 
polymorphs (7, 16-21). The main advantage of using droplets for crystal formation is that a 59 
small volume of solution can be isolated in an easy way such as using a manual or electronic 60 
pipette (20), or by segmenting the solution flow with an immiscible liquid or gas in a 61 
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microchannel (17-19). The supersaturation necessary to form crystals can then be generated 62 
by decrease the temperature of the droplets (7), adding an anti-solvent or a reactant (19) or 63 
via solvent evaporation (20). Each droplet can be considered as a single crystallizer allowing 64 
a systematic determination of the primary nucleation kinetic as well as an easier 65 
determination of the polymorphism of each crystal nucleated. Furthermore, the wells 66 
containing the droplets for evaporation-based devices can be chemically functionalized via 67 
self-assembled monolayers of specific organic compounds. In this way polymorphism can be 68 
controlled via templated heterogeneous nucleation (20, 21). Despite these advantages, the 69 
droplet-based devices that use micro-channels to mix immiscible liquids require the use of 70 
external pumps, precise flow control for the mixing of the two immiscible phases and 71 
complex microchannel geometry. Additionally, in the case of evaporation-based 72 
microfluidics, a controlled atmosphere around the droplets is necessary for a slow and 73 
controlled removal of the solvent.  74 
Both cooling and anti-solvent crystallization processes have been conducted in microfluidic 75 
channels with precise control of both temperature and solute concentration (12). Because of 76 
the reduced amount of crystallizing material needed, microfluidic devices are particularly 77 
convenient for the study of expensive compounds such as proteins (22, 23), or for safe 78 
handling of toxic and/or carcinogenic compounds (16). Compared to larger scale 79 
crystallizers, microfluidic crystallizers provide a micro-environment with laminar only 80 
mixing conditions that enable the formation of high quality crystals, with defined habit and 81 
limited structural defects or amorphicity. Such crystals can easily be analysed via optical 82 
microscopy, vibrational spectroscopy and, in some cases X-ray diffraction (16). Microfluidic 83 
devices are also particularly suited for polymorph screening. In fact, the reduced volume and 84 
the absence of turbulent mixing promotes primary over secondary nucleation and favours the 85 
discovery of a larger number of polymorphs and co-crystals (13-16). Furthermore, in small 86 
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volumes the nucleation and persistence of highly unstable polymorphs is more likely 87 
compared to large scale crystallizers (12-14, 16, 24). It is worth noticing that the rate of 88 
nucleation in small volumes is always slower than for large crystallizers, and the formation of 89 
crystals that are large enough to be analysed takes a longer time.  90 
Despite the evident advantages of microfluidics technologies, current devices remain 91 
expensive to produce at small scale, require bulky fluid handling equipment and present 92 
solvent-compatibility issues.  93 
In this work a novel multi-microfluidic platform for the generation of individual separated 94 
crystals (MMicroCryGen) that allows rapid and facile screening for polymorphism and 95 
crystal habit from a small sample volume is presented for the first time. In contrast to existent 96 
droplet-based microfluidic devices for polymorph screening (17-20) the MMicroCryGen does 97 
not require external pumps as sample is loaded by capillary action (similar to a conventional 98 
‘dipstick’ test) and crystals are generated by cooling, with smoother control of the 99 
supersaturation during nucleation. 100 
The MMicroCryGen device shown in Figure 1a was specifically designed to perform 101 
multiple cooling crystallization experiments in parallel, with the option of real-time, in-situ 102 
observation of the crystals using optical or spectroscopic sensors. This platform can be used 103 
for the screening of hydrates, salts and co-crystals, which are often used as expedients to 104 
improve the rate of dissolution and solubility of an API, as well as to study the morphology 105 
of the crystals in different solvents. 106 
The main consumable of the MMicroCryGen is a set of multiplex, microfluidic strips 107 
obtained via cutting a longer MicroCapillary Film (MCF). The MCF is a flat film containing 108 
an array of ten parallel microcapillaries fabricated from fluorinated ethylene propylene co-109 
polymer (Teflon-FEP®) using a novel continuous melt-extrusion process (25, 26). Photos of 110 
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the MCF strips are shown in  Figure 1b and c. Due to the geometry and optical properties of 111 
FEP-Teflon®, the microcapillaries are uniquely transparent in a very broad range of 112 
wavelengths including UV, VIS and NIR. Additionally, the MCF material is available in 113 
different inner internal diameters as reported elsewhere (27). Although FEP-Teflon® is 114 
naturally hydrophobic, internal coating of the microcapillaries with a hydrophilic hydrogel 115 
(28) enables the aspiration of fluid sample from a conventional microtiter plate by capillary 116 
action. Small volumes of API solutions (around 25 µL) can be prepared and aspirated into the 117 
microcapillaries without the use of pumps or syringes, similarly to conventional ‘dip stick’ 118 
tests. The small volume, low cost, transparency and hydrophilicity of the MCF material 119 
makes it an optimal consumable capillary element for the MMicroCryGen platform. The 120 
device uses a Peltier heat exchanger for carrying out controlled cooling crystallizations, 121 
enabling the study of both crystal morphology and polymorphism. In this work, the 122 
MMicroCryGen platform was validated by carrying out polymorph screening of succinic acid 123 
(SA) and ortho-aminobenzoic acid (OABA) (29-32), by determining the effect of o-toluic 124 
acid (OTA) on the polymorphism of OABA and by studying the formation of hydrates of 125 
piroxicam and co-crystals of p-Toluenesulfonamide (p-TSA) and Triphenylphosphine oxide 126 
(TPPO) (33). The data presented show that the MMicroCryGen is a valuable microfluidic 127 
solution for facile polymorph screening of APIs since it requires a smaller amount of drugs 128 
and solvents and considerably less and cheaper additional instrumentation compared to 129 
standard techniques. The device can be particularly useful during the early stages of drug 130 
development when only a small amount of material is available and for the study of toxic, 131 
genotoxic or carcinogenic APIs. 132 
 133 
Experimental 134 
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Materials 135 
For the screening experiments succinic acid (SA, from Sigma Aldrich, >99.0 % purity), 136 
ortho-aminobenzoic acid (OABA, from Sigma Aldrich, purity >98%), piroxicam (from 137 
Hangzhou Hyper Chemicals Limited, 99 % purity, anhydrous), o-toluic acid, (OTA, from 138 
Sigma Aldrich, 99% purity) and p-Toluenesulfonamide (p-TSA, 99 %) and 139 
triphenylphosphine oxide (TPPO, 99 %) was sourced from Sigma-Aldrich (Dorset, UK) and 140 
used as received. Deionized water (Millipore ultrapure water system) isopropyl alcohol (IPA 141 
99.97 % grade, Fisher Scientific, Loughborough, UK), acetone (Fisher Scientific, >99.98 % 142 
grade) and acetonitrile (Fisher Scientific, grade 99.9 %) were used as solvents.  143 
Multi-Microfluidic Crystal Generator (MMicroCryGen) 144 
Figure 2 shows the miniaturised MMicroCryGen device, developed and built in house at 145 
Loughborough University (UK). The main element is a re-usable frame (60.0 mm×78.8 mm, 146 
as shown in the drawings provided in the Supporting Information) composed of an 147 
aluminium plate, a central transparent Perspex cover and two side aluminium edges used for 148 
sealing the MCF strips and keeping them in a flat position (Figure 2a and 2d). The frame has 149 
8 slots for the insertions of 70-80 mm long MCF strips. The slots are spaced by 8.36 mm 150 
centre-to-centre, enabling the direct interface with a 96 wells microplate (Figure 2d). Each 151 
MCF strip has an internal volume of approximately 25 µL and each 2.5 µL microcapillary 152 
can be considered as a single crystallizer with no mixing. Although the MMicroCryGen was 153 
operated manually, it offers the opportunity for easy automation with a robot arm, and does 154 
not require any fluid handling equipment/pumps. The MCF strips are kept in a flat position 155 
on the plate and sealed at both ends to avoid solvent evaporation by compressing the central 156 
Perspex cover and the two lateral aluminium edges with three sets of four screws. The lateral 157 
edges are provided with 8 pointy protrusions that compress both edges of the MCF strips. 158 
Although in this work the whole frame was kept in position using three sets of screws (Figure 159 
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2b), the design could be further simplified with a one-step, ‘clip’ mechanism. The capillaries 160 
could be observed in real time through the Perspex cover using optical or spectroscopic 161 
sensors.  162 
The whole aluminium frame containing the MCF strips lay on a polyoxymethylene plate that 163 
contains a Peltier unit for temperature control (Meerstetter Engineering TEC-1090, Rubigen, 164 
Switzerland, shown in Figure 2b). The Peltier element (ThermaTECTM Series HT4, Laird 165 
Technologies, London United Kingdom) allows a range of temperatures in the 166 
microcapillaries between -20 and 120 °C and a maximum cooling rate of 5 °C/min. The 167 
Peltier unit is connected to a fan (BIG Shuriken 2, model SCBSK-2100 purchased from 168 
Scythe, Tokyo, Japan) and a controller (Meerstetter Engineering TEC-1091 running with 169 
TEC Service v3.0) for temperature regulation. Multiple units could be arranged in parallel 170 
and controlled independently for a higher number of simultaneous experiments. 171 
  172 
 173 
Fabrication of hydrophilic microfluidic, MCF strips  174 
The MCF material was manufactured by Lamina Dielectrics Ltd (Billingshurst, West Sussex, 175 
UK) from Teflon® FEP (Dupont, USA) and consists of an array of 10 parallel 176 
microcapillaries with a mean hydraulic diameter of 206 ± 12.6 µm (34). The raw MCF strips 177 
are hydrophobic (28), therefore they would require a pressure driven flow for sample loading; 178 
however in this work the MCF strips were made hydrophilic by coating the inside of each 179 
capillary with an hydrogel, poly(vinyl alcohol) (PVOH) (28). In this way the MCF strips 180 
could be filled simply by capillary action (‘dip stick’ mode). During the coating procedure 181 
100 mL of an aqueous solution of PVOH (MW 13 000–23 000, >98 % hydrolysed from 182 
Sigma-Aldrich, Dorset, UK) with concentration of 5 mg/mL was recirculated through a 6 m 183 
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long MCF at a flowrate of 50 mL/h for 12-15 hrs using a FPLC P-500 Pharmacia Biotech 184 
(Piscataway, USA) pump and Upchurch flangeless tube fittings (Kinesis, Saint Neots, United 185 
Kingdom). After that, the PVOH coating was crosslinked with glutaraldehyde by manually 186 
filling the MCF strip with a freshly prepared solution of PVOH (5 mg/mL) containing 5 mM 187 
of glutaraldehyde (Sigma-Aldrich, UK) and 5 mM HCl (Sigma-Aldrich, UK). The solution 188 
was kept inside the strips for 2 hours at 37 °C, after which the MCF strips were manually 189 
washed and dried with air using a 50 mL syringe (34). 190 
Solid form screening experiments in the MMicroCryGen platform 191 
For each experiment different solutions were prepared and loaded in the MMicroCryGen 192 
platform using the same procedure. The central Perspex cover was positioned on the 193 
aluminium frame and secured with four screws, then 8 hydrophilic or hydrophobic MCF 194 
strips of 70-80 mm length were inserted in the slots. For hydrophilic strips, the frame was 195 
positioned vertically above a 96 wells microplate loaded with clear API solutions and then 196 
lowered in order to fully immerse the tip of each strip in the wells. For hydrophobic strips, 197 
the microcapillaries were aspirated using a multi-syringe aspiration device reported elsewhere 198 
(34). On both cases, after complete filling of the capillaries with solution, the frame was 199 
placed in horizontal position and the lateral aluminium edges were secured with 8 screws (4 200 
at each side), automatically sealing both ends of the microcapillaries. The frame containing 201 
the MCF strips was then placed on the Peltier heat exchanger and the desired temperature or 202 
cooling profile set from the temperature control software. On-line monitoring of the 203 
experiments was performed with a USB Microscope (5.0 Megapixels supplied by MAOZUA, 204 
China). The MMicroCryGen device allows 80 independent parallel crystallization 205 
experiments in one go, this can be easily further expanded by increasing the number of strips.  206 
Once crystals were formed within the microcapillaries, the whole frame was removed from 207 
the Peltier unit and the MCF strips were individually analysed for crystal morphology and 208 
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polymorphism. A Raman microscope DXR 780 nm (Thermo Scientific equipped with 209 
OMNIC 8 software) equipped with a Linkam hot-stage was used to identify the structure of 210 
the crystals produced.  211 
For the polymorph screening experiments succinic acid (SA) and ortho-aminobenzoic acid 212 
(OABA) were used as solid compounds. Only deionized water was the solvent for succinic 213 
acid, while mixtures of deionized water and isopropyl alcohol were used for OABA. A 214 
solution of SA in water with concentration of 0.145 g/g solvent was prepared at 50 ⁰C and 215 
loaded in one row of a standard 96-wells microplate before being interfaced with the 216 
MMicroCryGen. The MCF strips were then cooled down to 5.0 °C at a rate of -0.5 °C/min. 217 
For OABA polymorph screening solutions at different concentrations of OABA were 218 
prepared and loaded into the capillaries at 60 °C, before being cooled down to 3.0 °C at a rate 219 
of -1.0 °C/min.  220 
Piroxicam in mixtures of deionized water and acetone was used in the hydrate screening 221 
experiments. Four solutions at different concentrations of piroxicam as well as solvent 222 
composition were prepared at 50 °C and loaded in duplicated MCF strips. The temperature 223 
was reduced to 3.0 °C at a rate of -1.0 °C/min.  224 
In the co-crystal screening experiments, p-Toluenesulfonamide and triphenylphosphine oxide 225 
were used with acetonitrile as solvent. Two solutions containing both components in specific 226 
stoichiometric ratios were prepared at 50.0 °C, and each loaded into four MCF strips. After 227 
that, the temperature was reduced to 3.0 °C at a rate of -1.0 °C/min.  228 
Finally, a set of experiments was conducted in the presence of o-toluic acid (OTA) in order to 229 
determine the effect of a structurally related additive on the crystallization of OABA. Four 230 
different aqueous solutions with concentration of OABA of 0.010 g/g water and different 231 
Page 10 of 30Lab on a Chip
La
b
on
a
C
hi
p
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
14
 Ju
ne
 2
01
8.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f B
at
h 
on
 6
/2
1/
20
18
 1
1:
02
:3
0 
A
M
. 
View Article Online
DOI: 10.1039/C8LC00301G
ratios OTA/OABA w/w were prepared at 50 ⁰C and loaded into the MCF strips. After that the 232 
temperature was reduced to 5.0 °C at a rate of -1.0 °C/min. 233 
In all experimental sets, the MMicroCryGen was further incubated overnight at 5.0 °C 234 
enabling full growth of crystals upon completion of the cooling stage.  235 
 236 
Results and discussion 237 
Polymorph screening of SA and OABA 238 
SA is known to have two polymorphic forms, α and β, which are enantiotropically related. 239 
The triclinic α-form is usually obtained by solid transformation from the β-form at 240 
temperatures above 137 °C while the monoclinic β-form is the polymorph that generally 241 
precipitates from water in various morphologies (29, 30). Microphotographs for SA crystals 242 
nucleated in the MMicroCryGen platform are shown in Figure 3b-3e, whereas Figure 3a 243 
shows plate-like crystals of β-form only nucleated from an aqueous solution of the same 244 
concentration in a 350 mL vessel with overhead stirring (29). Both high aspect ratio needles 245 
and plate-like crystals were observed in the MCF strips. Raman spectroscopy analysis (Figure 246 
4) confirmed the needle SA crystals were of α-form. The spectra of these crystals were also 247 
compared with those obtained from hot-stage experiments performed in the available Raman 248 
microscope. SA β-form crystals were heated up above the transition temperature of 137 ⁰C 249 
and then quickly cooled down to ambient temperature to allow the formation of the α-form on 250 
the hot-stage. Crystallisation in the MCF strips resulted in formation of SA crystals in their α-251 
form, which is usually not observed in cooling crystallization in aqueous solutions. This is 252 
presumably due to both the reduced volume and the absence of convection and turbulent 253 
mixing in the microfluidic strips of the MMicroCryGen device. Such conditions promote 254 
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primary over secondary nucleation, allowing the formation of a larger number of possible 255 
crystal structures, which is ideal for polymorph screening.  256 
 257 
The Raman spectra for both polymorphs of SA obtained in the MCF strips are shown in 258 
Figure 4, and compared to the spectrum of an empty microcapillary. FEP-Teflon® has 259 
distinct, clear peaks that can be easily identified and subtracted from the total final spectra; 260 
strong intensity FEP-Teflon® peaks can be found at values of Raman shift of 290, 385, 730, 261 
1225, 1300, 1380 cm-1. Depending on the objective and the size of the analysed crystals, it is 262 
possible to focus the Raman laser on a single crystal, avoiding the signal from the MCF strip. 263 
Both hydrophilic and hydrophobic capillaries were tested and no differences were observed 264 
in respect to SA polymorph formation. In fact, both structures were always obtained, 265 
suggesting that the chemistry of the capillary’s inner surface did not have a templating effect 266 
on the nucleation of this compound. 267 
 268 
Polymorph screening in different solvent mixtures was performed with OABA. The solvent 269 
compositions and OABA concentrations for each MCF strip are summarised in Table 1. In 270 
contrast to OABA crystallisation experiments previously conducted at larger scale, where 271 
only form I and II could be precipitated in water/IPA mixtures (31), all three known 272 
polymorphs of OABA were obtained in the capillaries, similarly to what was observed with 273 
SA. It can also be noted that, due to the slower kinetics of nucleation in small volumes, some 274 
capillaries did not show any visible crystals in the time scale used for experiments (around 275 
18-24 hrs). 276 
 277 
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Table 1: Experimental conditions and results for polymorph screening of OABA. 278 
MCF strip 
number 
Solvent composition  
(% of IPA in water, w/w) 
OABA concentration 
(g/g solvent) 
Crystals nucleated in 
each MCF strip 
1 0 0.010 0 
2 2%  0.010 1 (form I) 
3 5% 0.010 0 
4 10%  0.015 0 
5 15%  0.020 2 (form II) 
6 20%  0.030 2 (form II) 5 (form III)  
7 25%  0.055 4 (form II) 2 (form III)  
8 30%  0.080 1 (form II) 3 (form III)  
 279 
The MMicroCryGen device allowed to identify all the three known forms of OABA from a 280 
small amount of material, demonstrating the advantage of using this novel methodology for 281 
polymorph screening. The area in the Raman spectrum that unequivocally identifies the three 282 
OABA polymorphs is between 1500 and 1700 cm-1 (Figure 5). Form I presents a peak at 283 
1665 cm-1 and a doublet at 1600 cm-1, form II has a strong peak at 1565 cm-1 and form III 284 
presents the same peak but shifted to 1560 cm-1. Finally, form III is characterized by a strong 285 
peak at 1610 cm-1, which is not present in form I and it is weaker in form II. 286 
 287 
The polymorphs screening experiments performed in the MMicroCryGen platform show the 288 
advantage of using small volumes in the absence of mixing for the discovery of new crystal 289 
structure.   290 
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Hydrate detection for Piroxicam 291 
Piroxicam was crystallized in different mixtures of acetone and water in order to identify the 292 
possible polymorphs and confirm the presence of hydrate forms. Table 2 shows the 293 
experimental conditions and the different polymorphs identified by Raman spectroscopy, all 294 
known polymorphs and the hydrate form (35-37) were detected in the microcapillaries. 295 
Microscopic images of the two polymorphs are shown in Figure 6b, with the thin needles 296 
characteristic of form II clearly distinguishable from the prismatic form I crystals. The 297 
monohydrate form of piroxicam was obtained in all solutions containing water. These 298 
crystals have a characteristic bright yellow colour as shown in Figure 6a.  299 
 300 
Table 2: Experimental conditions and results for polymorph screening of piroxicam. 301 
MCF strip 
number 
Solvent composition 
(% w/w) 
Concentration 
(g/g solvent) 
Crystals nucleated in each MCF 
strip 
1-2 100% acetone 0.040 Anhydrous form I and form II 
3-4 5% water in acetone 0.035 Anhydrous form II (needles) and 
monohydrate (prism) 
5-6 20% water in acetone 0.013 Piroxicam monohydrate 
7-8 30% water in acetone 0.009 Piroxicam monohydrate 
 302 
Raman spectroscopy was also used to distinguish among the polymorphs and the 303 
monohydrate form of piroxicam within the MCF strips. Figure 6c shows the region between 304 
1500 and 1700 cm-1, where the three forms can be identified without interference from the 305 
FEP-Teflon®. The monohydrate form is characterized by a single strong peak at 1590 cm-1, 306 
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whereas form I has a high intensity peak at 1520 cm-1 and finally, form II is the only 307 
polymorph with a peak at 1540 cm-1. 308 
 309 
In the case of piroxicam, the MMicroCryGen enabled simultaneous identification of the two 310 
known polymorphs and the hydrate form in a single experiment with four different solutions 311 
of piroxicam in acetone and water mixtures.  312 
Screening for co-crystals 313 
A further set of experiments was carried out aiming to demonstrate the application of the 314 
MMicroCryGen device to identify co-crystal structures, using p-Toluenesulfonamide (p-315 
TSA) and Triphenylphosphine oxide (TPPO) as model compounds.  316 
 317 
Table 3: Experimental conditions and structures obtained during the screening of TSA/TPPO co-crystals. 318 
Solvent composition 
(% w/w) 
Concentration 
p-TSA 
(g/g solvent) 
Concentration 
TPPO  
(g/g solvent) 
Crystals nucleated in each MCF 
strip 
100% acetonitrile 0.02987 0.01492 3:2 co-crystal form 
100 % acetonitrile 0.01154 0.01489 1:1 co-crystal form 
 319 
The two co-crystals known for those chemicals, with molecular ratio p-TSA/TPPO 3:2 and 320 
1:1 (33), were quickly and successfully identified in a single experiment in the 321 
MMicroCryGen device, as confirmed by Raman spectroscopy according to data available 322 
from literature (33). Experimental conditions are described in Table 3, whereas the Raman 323 
spectra of the two co-crystal forms obtained are shown in Figure 7. The Raman spectra for 324 
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pure p-TSA and TPPO were compared to data available in literature (33, 38), confirming the 325 
formation of two co-crystal forms. The characteristic regions of the Raman spectrum for the 326 
unequivocal identification of the two co-crystal forms are shown in Figure 7. Characteristic 327 
peaks for the 1:1 co-crystal are located at 317, 460, 507, 934 and 1151 cm-1, whereas the 3:2 328 
co-crystal is characterized by specific peaks at 310, 915 and 1149 cm-1(Figure 7). 329 
These experimental demonstrate the use of ‘dip stick’ microcapillaries for discovery of new 330 
co-crystal structures. Furthermore, the use of the MMicroCryGen platform allowed the 331 
identification of such co-crystal forms running a single experiment, with the use of limited 332 
amount of chemicals as well as solvents.  333 
 334 
Screening of the effect of additives on polymorphism 335 
Additives can have an effect on the polymorphic outcome of crystallization processes. These 336 
additives can act by inhibiting nucleation or growth of a certain polymorph of the main 337 
crystallizing compound, therefore stabilizing a different form. They can also stereo-338 
selectively bind to specific surfaces of the targeted crystal nuclei, inhibiting their growth and 339 
therefore modifying the morphology of the crystals (32). The MMicroCryGen device was 340 
used to determine the effect of a structurally related additive (o-toluic acid, OTA) on the 341 
polymorphic outcome of OABA. Experiments at larger scale conducted with this compound 342 
and a similar molecule (benzoic acid) showed that a structurally related additive promoted 343 
nucleation of OABA form III, which can normally be obtained only by sublimation or 344 
polymorphic transformation at temperatures higher than the transition one (around 60 ⁰C) 345 
(32). Four aqueous solutions at different ratios OTA/OABA were loaded into the MCF strips 346 
before starting the cooling profile. Table 4 shows the polymorphs detected in the capillaries.  347 
 348 
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Table 4: Polymorphic outcome of cooling crystallization of OABA in the presence of the structurally related 349 
molecule OTA. 350 
MCF strips 
number 
Ratio 
OTA/OABA 
w/w 
OABA polymorphs identified 
in MCF 
1-2 0 Form I and II 
3-4 5% Form I, Form II, Form III 
5-6 10% Form III 
7-8 15% Form III 
 351 
 352 
Similarly to previously reported observations at larger scale experiments with benzoic acid 353 
(32), the addition of a structurally related additive promotes the formation of OABA form III 354 
in water. In fact, only form I and II were nucleated in water in the absence of additive, 355 
whereas preferential nucleation of only form III could be observed at increasing 356 
concentrations of OTA. This indicates that, similarly to benzoic acid, OTA has an effect on 357 
the polymorphic outcome of OABA crystals generated via cooling. Crystallization 358 
experiments in the MMicroCryGen platform allowed easier determination of the effect of a 359 
structurally related additive on the crystallization of OABA using a considerably lower 360 
amount of solvent and materials compared to experiments conducted at larger scale (32). 361 
Conclusions 362 
The presented microfluidic MMicroCryGen crystallization device represents a valuable novel 363 
solution for polymorph and co-crystal screening of small molecules, requiring a smaller 364 
amount of compound and solvents and considerably fewer and cheaper fluidics and electronic 365 
instrumentation compared to standard microfluidic techniques, as well as larger scale 366 
equipment. The device and methodology proposed has the ability of enabling up to 80 367 
parallel crystallization experiments without any pipetting or complex fluid handling, which 368 
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could be particularly useful during the early stages of drug development when only a small 369 
amount of material is available, and for the study of particularly toxic, genotoxic or 370 
carcinogenic APIs. In this paper the MMicroCryGen platform was validated for solid form 371 
screening of SA, OABA, Piroxicam and the TSA/TPPO system. All known polymorphs, 372 
hydrates and co-crystals of the systems studied were identified with a reduced number of 373 
experiments and using very small amounts of material. The MMicroCryGen platform could 374 
also be used for more complex experiments including the study of the effect of additives on 375 
crystal forms resulting from cooling crystallization.  376 
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 Figure 1: (a) Photographs of the MMicroCryGen unit with temperature controller for remote temperature setting; 
(b-c) Photographs of the MCF strips and detail of the 10 internal capillaries 
 
10 
capillaries 
for each 
MCF strip 
80 mm long MCF strips ready 
for use in the MMicroCryGen 
Temperature controller MMicroCryGen unit 
Controller software 
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 Figure 2: (a) Photograph showing the four elements of the removable frame of the MMicroCryGen platform; (b) 
Assembled frame; (c) Removable frame positioned on the Peltier element holder and fan; (d) Solutions loading 
procedure for hydrophilic capillaries. 
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Figure 3: (a) Microscopic image of β SA crystals obtained from water in a 350 mL stirred vessel; (b), (c) 
crystals of α SA inside an MCF strip; (d), (e) crystals of β SA inside an MCF strip. 
(a) 
(b) (c) 
(d) (e) 
Page 25 of 30 Lab on a Chip
La
b
on
a
C
hi
p
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
14
 Ju
ne
 2
01
8.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f B
at
h 
on
 6
/2
1/
20
18
 1
1:
02
:3
0 
A
M
. 
View Article Online
DOI: 10.1039/C8LC00301G
  
Figure 4: Raman spectra of the two polymorphs of SA inside an MCF strip and an empty capillary of MCF strip. 
Region (a) 2800- 3050 cm-1; (b) 1350-1500 cm-1 and (c) full spectrum. 
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Figure 5: (a) Raman spectra of the different polymorphs of OABA identified in the capillaries (b) Crystal of form 
III, (c) Crystals of form III on the top capillary and form II on the bottom one. 
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 Figure 6: (a) Piroxicam hydrate crystals nucleated from a solution of 30% water in acetone w/w, (b) crystals of 
Piroxicam anhydrous form II (needles) and monohydrate (prism) nucleated in a solution of 5% water in acetone w/w; 
(3) Raman spectra of form I, form II and piroxicam monohydrate. 
(a) (b) 
(c) 
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Figure 7: Raman spectra of the different forms of p-TSA/TPPO co-crystals identified in the capillaries. Regions 
between (a) 220-330 cm-1; (b) 350-560 cm-1; (c) 850-960 cm-1 and (d) 1100-1250 cm-1. 
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The MMicroCryGen allows single crystal generation and screening using 200 μL of solvent and 
without complex fluid handling (‘dipstick’ mode). 
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